Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 15/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CDK4 | P11802 | 1/20 | 0.41 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | EPHB2 | P29323 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4119705 | 0.77 | MEN1 (0.45) | CDK1MEN1KMT2ACDK4MAPK3 | |
| SCHEMBL29393606 | 0.75 | CDK1 (0.49) | CDK1CDK4MAPK3FBP1EPHB2 | |
| SCHEMBL3459248 | 0.75 | IGF1R (0.46) | CDK1EGFR | |
| SCHEMBL29215757 | 0.74 | MEN1 (0.49) | CDK1MEN1KMT2AEGFR | |
| SCHEMBL6211352 | 0.72 | MEN1 (0.66) | CDK1MEN1KMT2AEGFR | |
| SCHEMBL6675253 | 0.72 | MEN1 (0.62) | CDK1MEN1KMT2AEGFR | |
| SCHEMBL4175837 | 0.71 | SYK (0.51) | CDK1MEN1KMT2AEGFR | |
| SCHEMBL1774193 | 0.71 | IGF1R (0.68) | CDK1MEN1KMT2AEGFR | |
| SCHEMBL3982423 | 0.71 | CDK1 (0.58) | CDK1CDK4MAPK3EGFR | |
| SCHEMBL6640529 | 0.71 | EGFR (0.56) | MEN1KMT2AEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059511-A1 | SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | BAYER SCHERING PHARMA AG (DE) | 2008-07-10 | — | — | US | disclosed |
| WO-2008025556-A1 | SULPHOXIMIDES AS PROTEIN KINASE INHIBITORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167330-A1 | Carbamoylsulphoximides as protein kinase inhibitors | CABLES1, CKS2, CDK2AP1 | CDK1 6/4885MEN1 452/4885KMT2A 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.